We narrowed to 1,089 results for: plasmid

#105548-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CMVs.TurboRFP.WPRE.RBG (#105548). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.TurboRFP.WPRE.RBG plasmid DNA. CMV-driven TurboRFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105532-AAV1

Ready-to-use AAV1 particles produced from pAAV.CMV.ffLuciferase.SV40 (#105532). In addition to the viral particles, you will also receive purified pAAV.CMV.ffLuciferase.SV40 plasmid DNA. CMV-driven ffLuciferase control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105530-rh10

Ready-to-use AAV rh10 (similar to AAV10) particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#84471-AAV8

Ready-to-use AAV8 particles produced from pAAV-RAM-d2TTA::TRE-ChR2-WPREpA (#84471). In addition to the viral particles, you will also receive purified pAAV-RAM-d2TTA::TRE-ChR2-WPREpA plasmid DNA. RAM-containing and TRE-driven, ChR2 H134R mutant fused to EYFP. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sorensen et al Elife. 2016 Sep 23;5. pii: e13918. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#198513-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#55637-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

March 18, 2024

Academic Institutions and Nonprofits only

#177673-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#106174-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 14, 2024

Academic Institutions and Nonprofits only

#172923-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 (#172923). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8f-P2A-mRuby3 plasmid DNA. hSyn-driven expression of calcium sensor jGCaMP8f in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aug. 24, 2023

Academic Institutions and Nonprofits only

#59331-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-EGFP (#59331). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-EGFP plasmid DNA. CAG-driven, Cre-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

July 12, 2023

Academic Institutions and Nonprofits only

#117383-AAV1

Ready-to-use AAV1 particles produced from pAAV-TRE-DIO-eYFP (#117383). In addition to the viral particles, you will also receive purified pAAV-TRE-DIO-eYFP plasmid DNA. Tet-inducible, Cre-dependent eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#50472-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine (#50472). In addition to the viral particles, you will also receive purified pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine plasmid DNA. GFAP-driven HA-tagged rM3D(Gs) and bicistronic mCitrine expression, for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#135633-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#83894-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only

#104493-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP7b-WPRE (#104493). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7b-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7b expression. jGCaMP7b expression exhibits the brightest resting fluorescence and can be used for imaging of small neuronal processes (dendrites and axons). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Nov. 14, 2019

Academic Institutions and Nonprofits only

#174112-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#169128-AAV1

Ready-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.

Georg Nagel

Zhang et al Nature. 2021 Sep;597(7875):245-249. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#37825-AAV6

Ready-to-use AAV6 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#213815-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213855-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only